Stock APLM APOLLOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
0.2117 USD -3.77% Intraday chart for Apollomics, Inc. +3.02% -78.06%
06-04 Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting CI
05-08 Apollomics, Inc. Appoints Robert Lin to the Board of Directors CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apollomics Announces Vebreltinib Data At the 2024 American Society of Clinical Oncology Annual Meeting
Apollomics, Inc. Appoints Robert Lin to the Board of Directors
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene
Predicine, Inc. Announces Collaboration with Apollomics, Inc. to Develop Predicinecare as A Companion Diagnostic Assay in Lung Cancer
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Apollomics Gets Nasdaq Noncompliance Notice
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Top Premarket Gainers
Apollomics Announces Two New Cohorts in Global Phase 2 Sparta Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with Met Dysregulation
Sector Update: Health Care Stocks Slip in Late Afternoon
Sector Update: Health Care
Apollomics Shares Soar on Experimental Drug's Efficacy in Brain Tumor Patient
Wall Street Set to Open Higher Friday; Core Inflation Rises 0.3% Matching Forecast
US Futures Mixed as Investors Look Toward Personal Income, Consumer Sentiment Reports
Top Premarket Gainers
Apollomics Inc. Announces Report of Activity of Vebrelinib in Glioblastoma Multiforme with PTPRZ-MET Fusion
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%
Apollomics, Inc. Announces Presentations of Vebreltinib Data at ESMO 2023
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Apollomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLM Stock
  4. News Apollomics, Inc.
  5. Other languages